Phase III long-term safety study of soluble ferric pyrophosphate (SFP) in dialysate in patients with chronic kidney disease receiving haemodialysis
Latest Information Update: 21 Jan 2016
At a glance
- Drugs Ferric pyrophosphate (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions; Registrational
- Sponsors Rockwell Medical Technologies
- 19 Jan 2016 Data will be presented at the National Kidney Foundation Spring Clinical Meeting 2016, according to a Rochwell Medical Technologies media release.
- 13 Feb 2014 New trial record